Evidence map›Paper›PMID 38573494›Full record

ArticleHuman cell2024

Establishment of a human ovarian clear cell carcinoma cell line mutant in PIK3CB but not PIK3CA.

Hitomi Hoshino, Daisuke Inoue, Akiko Shinagawa, Hisato Yoshida, Shohei Shigeto, Kazuyuki Matsuda, Tomoya O Akama, Yoshio Yoshida, Motohiro Kobayashi

Open access · hybridAbstract read
In one paragraph

Article in Human cell, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Hitomi Hoshino *Department of Tumor Pathology, Faculty of Medical Sciences, University of Fukui, 23-3 Matsuoka-Shimoaizuki, Eiheiji, Fukui, 910-1193, Japan.
Daisuke Inoue *Department of Obstetrics and Gynecology, Faculty of Medical Sciences, University of Fukui, Eiheiji, Japan.
Akiko ShinagawaDepartment of Obstetrics and Gynecology, Faculty of Medical Sciences, University of Fukui, Eiheiji, Japan.
Hisato YoshidaDepartment of Tumor Pathology, Faculty of Medical Sciences, University of Fukui, 23-3 Matsuoka-Shimoaizuki, Eiheiji, Fukui, 910-1193, Japan.
Shohei ShigetoDepartment of Laboratory Medicine, Shinshu University Hospital, Matsumoto, Japan.
Kazuyuki MatsudaDepartment of Clinical Laboratory Sciences, School of Health Sciences, Shinshu University, Matsumoto, Japan.
Tomoya O AkamaDepartment of Pharmacology, Kansai Medical University, Hirakata, Japan.
Yoshio YoshidaDepartment of Obstetrics and Gynecology, Faculty of Medical Sciences, University of Fukui, Eiheiji, Japan.
Motohiro KobayashiDepartment of Tumor Pathology, Faculty of Medical Sciences, University of Fukui, 23-3 Matsuoka-Shimoaizuki, Eiheiji, Fukui, 910-1193, Japan. motokoba@u-fukui.ac.jp.ORCID http://orcid.org/0000-0002-7607-0801
University of Fukui · JPKansai Medical University · JPShinshu University · JPShinshu University Hospital · JP

Funding

Japan Society for the Promotion of Science 21H02702
6 · The paper itself

Abstract

A human ovarian clear cell carcinoma cell line was established from a 46-year-old Japanese woman. That line, designated MTC-22, has proliferated continuously for over 6 months in conventional RPMI 1640 medium supplemented with 10% foetal bovine serum and has been passaged over 50 times. MTC-22 doubling-time is ~ 18 h, which is much shorter than most ovarian clear cell carcinoma lines reported to date. Morphologically, MTC-22 cells exhibit polygonal shapes and proliferate to form a monolayer in a jigsaw puzzle-like arrangement without contact inhibition. Ultrastructurally, cells exhibit numerous intracytoplasmic glycogen granules and well-developed mitochondria. G-band karyotype analysis indicated that cells have a complex karyotype close to tetraploid. We observed that the expression pattern of a series of ovarian carcinoma-related molecules in MTC-22 cells was identical to that seen in the patient's tumour tissue. Notably, MTC-22 cells, and the patient's carcinoma tissue, expressed low-sulphated keratan sulphate recognised by R-10G and 294-1B1 monoclonal antibodies, a hallmark of non-mucinous ovarian carcinoma, and particularly of clear cell ovarian carcinoma. Moreover, characteristic point mutations-one in ARID1A, which encodes the AT-rich interaction domain containing protein 1A, and the other in PIK3CB, which encodes the catalytic subunit of phosphoinositide 3-kinase-were seen in the patient's tumour tissue and retained in MTC-22 cells. Collectively, these findings indicate that MTC-22 cells could serve as a valuable tool for investigating the pathophysiology of ovarian clear cell carcinoma, particularly that harbouring PIK3CB mutations, and for developing and validating new diagnostic and therapeutic approaches to this life-threatening malignancy.

Indexed as

Adenocarcinoma, Clear CellClass I Phosphatidylinositol 3-KinasesOvarian NeoplasmsCell Line, TumorCell ProliferationDNA-Binding ProteinsFemaleHumansMiddle AgedMutationNuclear ProteinsPhosphatidylinositol 3-KinasesPoint MutationTranscription FactorsARID1A protein, humanClass I Phosphatidylinositol 3-KinasesDNA-Binding ProteinsNuclear ProteinsPhosphatidylinositol 3-KinasesPIK3CA protein, humanTranscription FactorsARID1ACell lineClear cell carcinomaKeratan sulphateOvaryPIK3CB

Identifiers

PMID38573494
PMCPMC11194194
OpenAlexW4393931510

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.